Mangoceuticals secures exclusive US/Canada rights to Diabetinol®; 1M shares and royalty

MANGOCEUTICALS, INC.

Exclusive rights to Diabetinol® in US & Canada; nutraceutical for blood glucose/HbA1c management.
Consideration: 1M restricted shares (~16% dilution) plus 10% net sales revenue.
Term perpetual; if <$1.5M sales by Dec 2026, rights become non-exclusive; can extend 12 mo with $5M payment.
Raised $200k via sale of 80k shares at $2.50/share to accredited investor.
Clinical study: 14.3% reached HbA1c targets (vs 0% placebo); 83.3% reached SBP goals (vs 60%).

item 1.01 item 3.02 item 7.01 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.